Skip to content

Precigen PGEN Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Gilead Sciences logo
Gilead SciencesGILD
$23.52B+22.7%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$636.01M+5.2%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$1.11B-24.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$613.98M-10.1%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's total equity?
Precigen (PGEN) reported total equity of $20.24M in Q1 2026.
How has Precigen's total equity changed year-over-year?
Precigen's total equity increased by 243.9% year-over-year, from -$14.06M to $20.24M.
What is the long-term trend for Precigen's total equity?
Over 5 years (2020 to 2025), Precigen's total equity has grown at a -20.8% compound annual growth rate (CAGR), from $67.17M to $20.91M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.